Michael Bradshaw, MD
Dermatology · San Diego, CANPI 1861646267
Payments from drug & device makers
Across 813 payments — averaging $175.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$105K
- Bristol Myers Squibb$16K
- E.r. Squibb & Sons, L.L.C.$7K
- Pfizer$4K
- Johnson & Johnson$1K
- Sanofi$1K
- plus $8K from 30 others
What the payments were for
- Consulting fees$9,9607%
- Speaking & faculty fees$108,35576%
- Travel & lodging$7,5615%
- Food & beverage$16,37311%
- Education$7221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 166 | $105,204 |
| Bristol Myers Squibb | 20 | $16,137 |
| E.r. Squibb & Sons, L.L.C. | 38 | $6,745 |
| Pfizer | 51 | $4,433 |
| Johnson & Johnson | 90 | $1,427 |
| Sanofi | 45 | $1,354 |
| AbbVie(2 entities) | 59 | $1,326 |
| Sun Pharmaceutical Industries Inc. | 42 | $750 |
| Incyte Corporation | 36 | $702 |
| Regeneron Healthcare Solutions, Inc. | 18 | $516 |
| UCB, Inc. | 17 | $479 |
| LEO Pharma Inc. | 18 | $431 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 37 | $409 |
| Arcutis Biotherapeutics, Inc. | 17 | $353 |
| Galderma Laboratories, L.p. | 26 | $320 |
| Almirall LLC | 24 | $302 |
| Prugen, Inc. Pharmaceuticals | 26 | $299 |
| Lilly USA, LLC | 20 | $248 |
| Sanofi-aventis U.S. LLC | 7 | $244 |
| Hill Dermaceuticals, Inc. | 1 | $235 |
| Dermavant Sciences, Inc. | 19 | $216 |
| Novartis | 11 | $193 |
| Dermira, Inc. | 7 | $158 |
| Regeneron | 1 | $126 |
| VYNE Pharmaceuticals Inc. | 6 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Genentech USA, Inc. | 1 | $28 |
| Boston Scientific | 1 | $27 |
| Promius Pharma LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Aclaris Therapeutics, Inc. | 1 | $20 |
| Mission Pharmacal Company | 1 | $18 |
| Journey Medical Corporation | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,971 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 17 | $152,810 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $110,165 |
| Dupixent PenDupilumab | 20 | $79,835 |
| OtezlaApremilast | 14 | $68,308 |
| Dupixent SyringeDupilumab | 13 | $46,273 |
| OpzeluraRuxolitinib Phosphate | 12 | $23,277 |
| Pimecrolimus | 13 | $8,321 |
| Fluocinonide | 147 | $5,464 |
| Tacrolimus | 27 | $2,902 |
| Ketoconazole | 119 | $1,881 |
| Triamcinolone Acetonide | 175 | $1,577 |
| Fluorouracil | 24 | $1,556 |
| Calcipotriene | 18 | $1,518 |
| Doxycycline Hyclate | 72 | $1,495 |
| Clindamycin Phosphate | 27 | $1,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $105,204 | $68,30814 claims |
| Incyte CorporationOpzelura | $702 | $23,27712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.
Other dermatology in San Diego
- Neal BhatiaSan Diego$5.1M
- Walter NahmSan Diego$4.7M
- Michelle PelleSan Diego$1.8M
- Tissa HataSan Diego$619K
- Arisa OrtizSan Diego$603K
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.